Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
Neurocrine Biosciences (NBIX) is set to participate in the 2024 Cantor Global Healthcare Conference on September 17, 2024, at 3:05 p.m. Eastern Time in New York. The company's presentation will feature Kyle Gano (Chief Business Development and Strategy Officer and CEO-elect), Matt Abernethy (Chief Financial Officer), and Todd Tushla (Vice-President of Investor Relations).
The event will be webcast live on Neurocrine's website and archived for approximately one month. Neurocrine Biosciences is a leading neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio includes FDA-approved treatments for tardive dyskinesia, Huntington's disease-associated chorea, endometriosis, and uterine fibroids, along with a robust pipeline of compounds in mid to late-phase clinical development.
Neurocrine Biosciences (NBIX) parteciperà alla 2024 Cantor Global Healthcare Conference il 17 settembre 2024 alle 15:05 ora orientale a New York. La presentazione dell'azienda includerà Kyle Gano (Chief Business Development and Strategy Officer e CEO designato), Matt Abernethy (Chief Financial Officer) e Todd Tushla (Vice-Presidente delle Relazioni con gli Investitori).
L'evento sarà trasmesso in diretta sul sito web di Neurocrine e sarà disponibile in archivio per circa un mese. Neurocrine Biosciences è un'importante azienda biopharmaceutical con un focus sulle neuroscienze, dedicata allo sviluppo di trattamenti per disordini neurologici, neuroendocrini e neuropsichiatrici. Il loro portafoglio include trattamenti approvati dalla FDA per la discinesia tardiva, la chorea associata alla malattia di Huntington, l'endometriosi e i fibromi uterini, insieme a una robusta pipeline di composti in fase clinica intermedia e avanzata.
Neurocrine Biosciences (NBIX) participará en la Conferencia Global de Salud 2024 de Cantor el 17 de septiembre de 2024 a las 3:05 p.m. hora del Este en Nueva York. La presentación de la compañía contará con Kyle Gano (Director de Desarrollo Empresarial y Estrategia y CEO electo), Matt Abernethy (Director Financiero) y Todd Tushla (Vicepresidente de Relaciones con Inversores).
El evento será transmitido en vivo en el sitio web de Neurocrine y archivado durante aproximadamente un mes. Neurocrine Biosciences es una empresa biofarmacéutica líder enfocada en las ciencias neurales, dedicada al desarrollo de tratamientos para trastornos neurológicos, neuroendocrinos y neuropsiquiátricos. Su cartera incluye tratamientos aprobados por la FDA para la discinesia tardiva, la corea asociada con la enfermedad de Huntington, la endometriosis y los fibromas uterinos, junto con un sólido pipeline de compuestos en desarrollo clínico de fase media a avanzada.
Neurocrine Biosciences (NBIX)는 2024 Cantor Global Healthcare Conference에 참여할 예정이며, 2024년 9월 17일 오후 3:05 동부 표준시에 뉴욕에서 발표할 것입니다. 회사의 발표에는 Kyle Gano (최고 사업 개발 및 전략 책임자 및 CEO 예정), Matt Abernethy (최고 재무 책임자), Todd Tushla (투자자 관계 부사장)가 포함됩니다.
이 행사는 Neurocrine의 웹사이트에서 실시간 스트리밍되며 약 한 달 동안 아카이브됩니다. Neurocrine Biosciences는 신경과학에 중점을 둔 선도적인 생물의약품 회사로, 신경계, 신경내분비 및 신경정신 장애 치료제를 개발하는 데 전념하고 있습니다. 이들의 포트폴리오에는 FDA 승인 치료제가 포함되어 있으며, 이는 지연성 운동장애, 헌팅턴병 관련 춤, 자궁내막증 및 자궁 섬유종에 대한 치료제를 포함하며, 중기에서 후기 임상 개발 중인 강력한 신약 파이프라인도 포함되어 있습니다.
Neurocrine Biosciences (NBIX) participera à la Conférence Mondiale de la Santé 2024 de Cantor le 17 septembre 2024 à 15h05, heure de l'Est, à New York. La présentation de l'entreprise mettra en vedette Kyle Gano (Directeur du développement commercial et de la stratégie et futur PDG), Matt Abernethy (Directeur financier) et Todd Tushla (Vice-président des relations avec les investisseurs).
L'événement sera diffusé en direct sur le site web de Neurocrine et archivé pendant environ un mois. Neurocrine Biosciences est une entreprise biopharmaceutique de premier plan axée sur les neurosciences, dédiée au développement de traitements pour les troubles neurologiques, neuroendocriniens et neuropsychiatriques. Leur portefeuille comprend des traitements approuvés par la FDA pour la dyskinésie tardive, la chorée associée à la maladie de Huntington, l'endométriose et les fibromes utérins, ainsi qu'un solide pipeline de composés en développement clinique de phase intermédiaire à tardive.
Neurocrine Biosciences (NBIX) wird an der 2024 Cantor Global Healthcare Conference am 17. September 2024 um 15:05 Uhr Eastern Time in New York teilnehmen. Die Präsentation des Unternehmens wird Kyle Gano (Chief Business Development and Strategy Officer und designierter CEO), Matt Abernethy (Chief Financial Officer) und Todd Tushla (Vizepräsident für Investor Relations) umfassen.
Die Veranstaltung wird live im Internet übertragen und etwa einen Monat lang archiviert. Neurocrine Biosciences ist ein führendes biopharmazeutisches Unternehmen mit Fokus auf Neurowissenschaften, das sich der Entwicklung von Behandlungen für neurologische, neuroendokrine und neuropsychiatrische Störungen widmet. Ihr Portfolio umfasst von der FDA genehmigte Behandlungen für tardive Dyskinesie, chorea bei Huntington-Krankheit, Endometriose und Gebärmutterfibrome sowie eine umfangreiche Pipeline von Verbindungen in der klinischen Entwicklungsphase mittlerer bis später Stadien.
- None.
- None.
The live presentation will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-the-2024-cantor-global-healthcare-conference-302244198.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When is Neurocrine Biosciences (NBIX) presenting at the 2024 Cantor Global Healthcare Conference?
Who will be presenting for Neurocrine Biosciences (NBIX) at the 2024 Cantor Global Healthcare Conference?
How can investors access Neurocrine Biosciences' (NBIX) presentation at the 2024 Cantor Global Healthcare Conference?
What are some of the FDA-approved treatments in Neurocrine Biosciences' (NBIX) portfolio?
What is the main focus of Neurocrine Biosciences (NBIX) as a biopharmaceutical company?
